Pharma deal flow collapsed 62 percent while AI startups hide in plain sight

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Pharma deal flow collapsed 62 percent while AI startups hide in plain sight

Listen for free

View show details

Pharma deal flow didn't collapse 62.5 percent last quarter — it just stopped filing as pharma. AI-native drug discovery companies like Recursion and Insitro are filing under "Other Technology" because their value lives in computational platforms, not clinical pipelines, which means healthcare funds tracking SEC codes are literally missing deals before they hit the committee. Total healthcare-adjacent deal count stayed completely flat at 74 deals, but if your allocation strategy runs on sector labels instead of manual tagging, you're benchmarking against a category that no longer describes where the actual capital is flowing.

No reviews yet